OHIM opens EU-wide enforcement database

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

OHIM opens EU-wide enforcement database

OHIM has launched an enforcement database, allowing trade mark owners and enforcement professionals to exchange information about IP infringements

The database project has been set up by the EU Observatory on Infringements of Intellectual Property Rights, which was transferred to OHIM from the European Commission almost 18 months ago.

Rights holders will be able to upload pictures and other information about products that are protected by trade marks or design rights that will help enforcement agencies to spot fake versions. There is no charge for using the service.

OHIM says that it is beginning to grant police in member states access to the database following the signing of a cooperation agreement between OHIM and Europol.

The enforcement database was paid for by OHIM’s €50 million Cooperation Fund, set up to use some of the Office’s surplus to fund IT tools for EU national and regional IP offices and users.

Rights holders who want to participate in the tool should email: Observatory.edb@oami.europa.eu.





more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Schwitulla is the head of litigation management at Nokia in Germany
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article